Medivation, Inc. (MDVN)

StockSouter (34.30) Submitted: 11/3/2009 2:59:08 PM : Start Price: $26.63 MDVN Score: +9.53

Stock is priced on MDV 3100 future revenue alone which gets you the dimebon chance for success for free

quinpeung (43.78) Submitted: 5/9/2009 8:56:40 AM : Start Price: $19.06 MDVN Score: -37.17

Dimebon may be the best candidate to treat Alzheimer's disease, which is not saying much. Nevertheless, current economic climate makes this red thumb a solid CAPS play.

FSaucy (99.81) Submitted: 3/4/2009 10:47:59 AM : Start Price: $14.70 MDVN Score: -51.92

Zero revenue + $400 M market cap = Lots of high hopes

lfjl (< 20) Submitted: 9/9/2008 3:31:57 PM : Start Price: $33.00 MDVN Score: -1.14

stock just climbed too high too fast, I don't expect it to stay here. Time to short.

bigreenmountain (< 20) Submitted: 8/6/2008 1:51:08 AM : Start Price: $14.98 MDVN Score: +124.33

effective new alzheimers drug

lcscarce (42.97) Submitted: 7/31/2008 10:38:48 PM : Start Price: $20.00 MDVN Score: +64.42

With the new data out on the positive reports on the new alzheimer's drug and a great management team, I feel this company will out perform the S&P due to the economic downturn. Also with the increase in alzheimer's victums the drug is needed, so this breaktrough is a positive step forward.

Hybr1d1nevstor (53.43) Submitted: 5/16/2008 12:09:02 AM : Start Price: $14.51 MDVN Score: +132.75

"Alzheimer's patients treated with the investigational drug Dimebon(TM) showed improvement in the key aspects of cognitive function over a one-year period compared with placebo."

On its way up - Target $24

mchrist152 (94.57) Submitted: 2/25/2008 12:08:30 AM : Start Price: $15.97 MDVN Score: +108.47

The phase II results for Dimebon were spectacular, but they were performed in Russia. Although Russia is suspect in a lot of ways (politically, ethically), they have always valued science and I think it is highly likely that these result are valid. If they are valid, how can this stock not shoot up 10 to 30 times in say 3 to 4 years as they bring the alzheimer's drug to market. This is clearly a speculation play but the upside is huge while the downside is zero.

tacitus52 (< 20) Submitted: 10/5/2007 6:56:07 PM : Start Price: $24.50 MDVN Score: +51.43

This company's fortunes are primarily tied to Dimebon, a drug that's been used for many years in Russia as an antihistamine, but which had been found effective in treating Alzheimer's. It's now in Phase Two testing, and so far it's been effective on all five endpoints of the tests. The fact that the drug has been used for some time for other purposes suggests it's unlikely to have negative side effects. Given the market for Alzheimer's drugs and the fact that there currently are no drugs which improve the disease, this is a potential blockbuster.

zzlangerhans (99.52) Submitted: 7/3/2007 8:37:00 PM : Start Price: $22.00 MDVN Score: -63.98

Market cap currently overinflated based on positive phase II data for Dimebon. Alzheimer's, like cancer, has been a very difficult player to beat in phase III regardless of phase II performance. Stock price may bump short term on noise about phase III trial for Dimebon, but I expect downward trail within a year due to lack of new positive data and absence of other advanced compounds in pipeline

RandysRetiring (42.33) Submitted: 6/21/2007 1:15:44 PM : Start Price: $19.18 MDVN Score: +84.23

I picked this one because Hilary Kramer like it & it Biotec.

henncoop (99.08) Submitted: 6/14/2007 1:19:35 PM : Start Price: $18.62 MDVN Score: +89.41

shows some great promise with new alzhiemer's drug ...other drugs in the pipeline as well

rfreyermuth (< 20) Submitted: 12/16/2006 10:41:49 AM : Start Price: $16.40 MDVN Score: -106.09

great management and great model